Impact of Disease Activity on Thyroid Diseases in Patients with Acromegaly: Basal Evaluation and Follow-up

Abstract

In patients with acromegaly, the exact incidence of thyroid disorders is still controversial and less is known about the impact of disease activity and successful treatment. To address this issue, we investigated 73 acromegalic patients (age 55 ± 13 yr; mean ± SD) by ultrasonography in comparison to an age-matched control group (54 ± 1 yr) in the same moderate iodine deficient area (retrospective study). These non-acromegalic volunteers (n = 199) were examined in the same clinic during a thyroid screening test. At the time of examination, 52 (71.2 %) of the acromegalic patients were active, 17 (23.3 %) were cured, and 4 (5.5 %) were controlled with somatostatin analogues. The prevalence of goiter (normal range < 18 ml female, < 25 ml male) was significantly higher (82.2 %) in the mixed group of acromegalics (active, well controlled, cured; n = 73) and in the active group (90.4 %) than in the control group (n = 199, 18.1 %, p < 0.001). Thyroid nodules were found in 63.0 % of the mixed group of acromegalics and in 71.2 % of patients with active disease (33.1 % in controls, p < 0.001). ^{99 m}Tc scintigraphy revealed thyroid autonomy in 9/73 (12.3 %) and cold nodules in 19/73 (26.0 %) patients. Thyroid cancer was diagnosed in 4 (5.5 %) of acromegalic patients (3 papillary and 1 follicular carcinoma). We found a weak correlation between the disease duration and the initial thyroid volume (r = 0.54, p < 0.0056).

Thirty-seven newly diagnosed acromegalics were followed over a period of 7.3 ± 4.1 years. 5 (13.5 %) of these patients remained active, 8 (21.6 %) were controlled with somatostatin analogues, and 24 (64.9 %) were cured. The mean age, sex distribution, disease duration, prevalence of TSH-deficiency, and initial thyroid volume (46 ± 11 ml in active, 42 ± 7 ml in controlled, and 45 ± 5 ml in cured patients) did not differ statistically between the three groups. In patients with active acromegaly, thyroid volume increased by 19.5 ± 8.1 %. In contrast, thyroid volume decreased in the group of medically controlled and cured acromegalics (- 21.5 ± 7.1 %; p < 0.005 and - 24.2 ± 5.7 %; p < 0.002, respectively). No correlation was found between thyroid volume and TSH levels, levothyroxine and/or iodide administration neither in TSH sufficient nor in TSH insufficient patients.

In conclusion, successful treatment of patients with active acromegaly decreases thyroid volume. Cold nodules and thyroid cancer frequently occur in acromegalic patients.

Key words

Acromegaly - thyroid diseases - disease activity

References

• 1 Ain K B, Taylor K D. Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro.  J Clin Endocrinol Metab. 1994;  78 1097-1102
• 2 Arosio M, Macchelli S, Rossi C M, Casati G, Biella O, Faglia G. Effects of treatment with octreotide in acromegalic patients - a multicenter Italian study. Italian Multicenter Octreotide Study Group.  Eur J Endocrinol. 1995;  133 430-439
• 3 Balkany C, Cushing G W. An association between acromegaly and thyroid carcinoma.  Thyroid. 1995;  5 47-50
• 4 Bechtner G, Schopohl D, Rafferzeder M, Gartner R, Welsch U. Stimulation of thyroid cell proliferation by epidermal growth factor is different from cell growth induced by thyrotropin or insulin-like growth factor I.  Eur J Endocrinol. 1996;  134 639-648
• 5 Bengtsson B A, Brummer R J, Eden S, Bosaeus I, Lindstedt G. Body composition in acromegaly: the effect of treatment.  Clin Endocrinol (Oxf). 1989;  31 481-490
• 6 Bengtsson B A, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984.  Acta Med Scand. 1988;  223 327-335
• 7 Brunn J, Block U, Ruf G, Bos I, Kunze W P, Scriba P C. Volumetric analysis of thyroid lobes by real-time ultrasound [author's transl].  Dtsch Med Wochenschr. 1981;  106 1338-1340
• 8 Cannavo S, Squadrito S, Finocchiaro M D, Curto L, Almoto B, Vieni A, Trimarchi F. Goiter and impairment of thyroid function in acromegalic patients: basal evaluation and follow-up.  Horm Metab Res. 2000;  32 190-195
• 9 Cheung N W, Boyages S C. The thyroid gland in acromegaly: an ultrasonographic study.  Clin Endocrinol (Oxf). 1997;  46 545-549
• 10 Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte A M, Petretta M, Salvatore M, Lombardi G. Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study.  J Clin Endocrinol Metab. 1999;  84 1518-1523
• 11 Colao A, Di Somma C, Spiezia S, Filippella M, Pivonello R, Lombardi G. Effect of growth hormone (GH) and/or testosterone replacement on the prostate in GH-deficient adult patients.  J Clin Endocrinol Metab. 2003;  88 88-94
• 12 Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart.  Clin Endocrinol (Oxf). 2001;  54 137-154
• 13 Colao A, Marzullo P, Spiezia S, Lombardi G. Acromegaly and prostate cancer.  Growth Horm IGF Res. 2000;  10 (Suppl A) S37-38
• 14 Derwahl M, Broecker M, Kraiem Z. Clinical review 101: Thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors.  J Clin Endocrinol Metab. 1999;  84 829-834
• 15 Dostalova S, Sonka K, Smahel Z, Weiss V, Marek J, Horinek D. Craniofacial abnormalities and their relevance for sleep apnoea syndrome aetiopathogenesis in acromegaly.  Eur J Endocrinol. 2001;  144 491-497
• 16 Ezzat S, Strom C, Melmed S. Colon polyps in acromegaly.  Ann Intern Med. 1991;  114 754-755
• 17 Gasperi M, Martino E, Manetti L, Arosio M, Porretti S, Faglia G, Mariotti S, Colao A M, Lombardi G, Baldelli R, Camanni F, Liuzzi A. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study.  J Endocrinol Invest. 2002;  25 240-245
• 18 Giustina A, Barkan A, Casanueva F F, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S. Criteria for cure of acromegaly: a consensus statement.  J Clin Endocrinol Metab. 2000;  85 526-529
• 19 Grimberg A, Cohen P. Growth hormone and prostate cancer: guilty by association?.  J Endocrinol Invest. 1999;  22 64-73
• 20 Grunstein R R, Ho K Y, Sullivan C E. Sleep apnea in acromegaly.  Ann Intern Med. 1991;  115 527-532
• 21 Hegedus L, Perrild H, Poulsen L R, Andersen J R, Holm B, Schnohr P, Jensen G, Hansen J M. The determination of thyroid volume by ultrasound and its relationship to body weight, age, and sex in normal subjects.  J Clin Endocrinol Metab. 1983;  56 260-263
• 22 Herrmann B L, Bruch C, Saller B, Bartel T, Ferdin S, Erbel R, Mann K. Acromegaly: evidence for a direct relation between disease activity and cardiac dysfunction in patients without ventricular hypertrophy.  Clin Endocrinol (Oxf). 2002;  56 595-602
• 23 Herrmann B L, Bruch C, Saller B, Ferdin S, Dagres N, Ose C, Erbel R, Mann K. Occurrence of ventricular late potentials in patients with active acromegaly.  Clin Endocrinol (Oxf). 2001;  55 201-207
• 24 Jenkins P J, Besser M. Clinical perspective: acromegaly and cancer: a problem.  J Clin Endocrinol Metab. 2001;  86 2935-2941
• 25 Junik R, Sawicka J, Kozak W, Gembicki M. Thyroid volume and function in patients with acromegaly living in iodine deficient areas.  J Endocrinol Invest. 1997;  20 134-137
• 26 Kasagi K, Shimatsu A, Miyamoto S, Misaki T, Sakahara H, Konishi J. Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland.  Thyroid. 1999;  9 791-796
• 27 Knudsen N, Bols B, Bulow I, Jorgensen T, Perrild H, Ovesen L, Laurberg P. Validation of ultrasonography of the thyroid gland for epidemiological purposes.  Thyroid. 1999;  9 1069-1074
• 28 Kopp P, Kimura E T, Aeschimann S, Oestreicher M, Tobler A, Fey M F, Studer H. Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters.  J Clin Endocrinol Metab. 1994;  79 134-139
• 29 Lombardi G, Colao A, Ferone D, Marzullo P, Landi M L, Longobardi S, Iervolino E, Cuocolo A, Fazio S, Merola B, Sacca L. Cardiovascular aspects in acromegaly: effects of treatment.  Metabolism. 1996;  45 57-60
• 30 Lombardi G, Colao A, Ferone D, Marzullo P, Orio F, Longobardi S, Merola B. Effect of growth hormone on cardiac function.  Horm Res. 1997;  48 38-42
• 31 Medina D L, Velasco J A, Santisteban P. Somatostatin is expressed in FRTL-5 thyroid cells and prevents thyrotropin-mediated down-regulation of the cyclin-dependent kinase inhibitor p27kip1.  Endocrinology. 1999;  140 87-95
• 32 Miyakawa M, Saji M, Tsushima T, Wakai K, Shizume K. Thyroid volume and serum thyroglobulin levels in patients with acromegaly: correlation with plasma insulin-like growth factor I levels.  J Clin Endocrinol Metab. 1988;  67 973-978
• 33 Orme S M, McNally R J, Cartwright R A, Belchetz P E. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.  J Clin Endocrinol Metab. 1998;  83 2730-2734
• 34 Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic Z, Marinkovic J. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group.  Clin Endocrinol (Oxf). 1998;  49 441-445
• 35 Quadbeck B, Pruellage J, Roggenbuck U, Hirche H, Janssen O E, Mann K, Hoermann R. Long-term follow-up of thyroid nodule growth.  Exp Clin Endocrinol Diabetes. 2002;  110 313-372
• 36 Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni Jr J F. Acromegaly and gastrointestinal cancer.  Cancer. 1991;  68 1673-1677
• 37 Rosenow F, Reuter S, Deuss U, Szelies B, Hilgers R D, Winkelmann W, Heiss W D. Sleep apnoea in treated acromegaly: relative frequency and predisposing factors.  Clin Endocrinol (Oxf). 1996;  45 563-569
• 38 Saji M, Tsushima T, Isozaki O, Murakami H, Ohba Y, Sato K, Arai M, Mariko A, Shizume K. Interaction of insulin-like growth factor I with porcine thyroid cells cultured in monolayer.  Endocrinology. 1987;  121 749-756
• 39 Takahashi S, Kawashima S, Seo H, Matsui N. Age-related changes in growth hormone and prolactin messenger RNA levels in the rat.  Endocrinol Jpn. 1990;  37 827-840
• 40 von Werder K. Acromegaly and thyroid.  J Endocrinol Invest. 2002;  25 930-931
• 41 Westermark K, Karlsson F A, Westermark B. Epidermal growth factor modulates thyroid growth and function in culture.  Endocrinology. 1983;  112 1680-1686
• 42 Williams T C, Kelijman M, Crelin W C, Downs T R, Frohman L A. Differential effects of somatostatin (SRIH) and a SRIH analog, SMS 201 - 995, on the secretion of growth hormone and thyroid-stimulating hormone in man.  J Clin Endocrinol Metab. 1988;  66 39-45
• 43 Wuster C, Steger G, Schmelzle A, Gottswinter J, Minne H W, Ziegler R. Increased incidence of euthyroid and hyperthyroid goiters independently of thyrotropin in patients with acromegaly.  Horm Metab Res. 1991;  23 131-134
• 44 Yashiro T, Ohba Y, Murakami H, Obara T, Tsushima T, Fujimoto Y, Shizume K, Ito K. Expression of insulin-like growth factor receptors in primary human thyroid neoplasms.  Acta Endocrinol (Copenh). 1989;  121 112-120
• 45 Yoshinari M, Tokuyama T, Kuroda T, Sato K, Okazawa K, Mizokami T, Okamura K, Fujishima M. Preserved thyroidal secretion of thyroxine in acromegalic patients with suppressed hypophyseal secretion of thyrotropin.  Clin Endocrinol (Oxf). 1992;  36 355-360